Protocols

Threshold blasted, restructures after a PhII failure; SQZ raises $16M

Robert Langer, photo credit: Chemical Heritage Foundation

Robert Langer, photo credit: Chemical Heritage Foundation

South San Francisco-based Threshold Pharmaceuticals $THLD says that its mid-stage trials for its cancer drug tarloxotinib proved to be a bust, and it’s now restructuring the company as a result. The company  – which saw its shares plunge 43% this morning – plans to shift focus to another effort adding evofosfamide to immune checkpoint inhibition. “Stewart M. Kroll, the Company’s Chief Operating Officer, and the members of the biostatistics and data management group will be departing the company,” says the biotech.

Boston-based SQZ, another in a string of spinouts from the lab of MIT’s Bob Langer, has rounded up a $16 million Series B. NanoDimension and Polaris Partners led the round, with participation from other existing and new investors.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,800+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->